Dr. Natalie Callander discusses updates in multiple myeloma treatment
![Dr. Natalie Callander](/sites/default/files/styles/max_750x750/public/2022-11/Callander_Natalie_20170202-RCT_6611_2017_02_02_med.jpg?itok=voawvqCr)
![Dr. Natalie Callander](/sites/default/files/styles/portrait_small_167x200_/public/2022-11/515.jpg?itok=ilkHGtl-)
There are new therapeutic options for refractory myeloma (which refers to myeloma that is not responsive to standard therapy or that fails to continue a response after a relapse) and relapsed myeloma (which recurs after a period of remission).
In a video for oncology professionals, Natalie Callander, MD, professor (CHS), described newly-available treatment regimens for multiple myeloma.
"Within the last two and a half years, a number of individual drugs as well as combinations have been FDA-approved for use," including combination therapies for which clinical trials have shown excellent response rates up to 93 percent of patients.
"We've got an embarrassment of riches [for treating multiple myeloma]," said Dr. Callander.
Resources:
- "Updates in the Treatment of Relapsed/Refractory Multiple Myeloma," Targeted Oncology, November 16, 2017